Introduction
Obesity and type 2 diabetes are common metabolic diseases known to be influenced by a large number of both environmental and genetic factors. 1 The susceptibility to these polygenic diseases may partly be explained by variants in genes regulating cellular signal transduction. 2 The autonomic nervous system, and the sympathetic nervous system in particular, has been shown to play a significant role in the regulation of basal metabolic rate (BMR) and body weight, 3 and polymorphisms in the human b 2 -adrenoceptor 4 or in the b 3 -adrenergic receptor genes 5, 6 have been reported to contribute to the susceptibility to obesity and type 2 diabetes mellitus. The adrenergic receptors are guanine nucleotide-binding regulatory protein (G-protein) coupled receptors found in the cell membrane of many tissues including the brain, sympathetic neurons, and the kidney, 7 where they mediate the physiological responses to catecholamines. At least nine adrenergic receptors have been identified on the basis of their affinity for different pharmacological agents, and they have been divided into a and b subtypes. 8 Three different a 2 -receptor subtypes, a 2A , a 2B and a 2C encoded by genes located on different chromosomes have been described. 9 -11 Agonists stimulating central a 2 -adrenoceptors in the brainstem lead to peripheral sympatoinhibition and reduction of elevated blood pressure, heart rate and plasma catecholamine levels, 12 whereas the activation of a 2B -adrenoceptors present in vascular smooth muscle cells causes vasoconstriction.
13 a 2 -adrenoceptors, (a 2 AR) are also known to influence energy metabolism through the inhibition of insulin secretion and lipolysis.
14 Previously, a polymorphism in the non-coding region of the a 2A -adrenoceptor gene has been reported to be associated with salt-sensitive hypertension in an African-American population. 15 More recently, a polymorphism in the a 2B -adrenergic receptor gene leading to a deletion of three glutamic acids from a glutamic acid repeat element (GluÂ12, amino acids 297 -309) present in the third intracellular loop of the receptor protein was identified. This polymorphism was found to be associated with reduced BMR in obese Finnish subjects. 16 In the present study, we examined the role of this deletion polymorphism as a contributor to body weight change in Finnish middle-aged non-diabetic control subjects and newly diagnosed type 2 diabetic patients by using data from a 10 y follow-up study.
Study design and methods

Study population
The original study population consisted of 144 non-diabetic control subjects (62 men and 82 women), and 133 newly diagnosed patients with type 2 diabetes (70 men and 63 women), aged 45 -64 y at baseline examination in 1979 -1981. Both groups were re-examined after 5 and 10 y. At baseline, all diabetic patients were treated with diet only. The frequency of drug treatment increased with time: at the 10 y examination, only 15 (17.9%) diabetic subjects were treated with diet only, 49 (58.3%) with oral hypoglycemic drugs, and 20 (23.8%) with insulin. The formation and representativeness of the baseline, 5 and 10 y study populations have been described earlier in detail. 17, 18 The non-diabetic control subjects of this study were randomly selected from the population register of the study area. The diagnosis of diabetes was made in the clinical setting, and confirmed by an oral glucose tolerance test according to the WHO diagnostic criteria. 19 Approval for the study was given by the Ethics Committee of the Kuopio University and Kuopio University Hospital. Informed consent was obtained from all the subjects studied.
During the 10 y follow-up, eight control subjects (three men and five women) and 36 diabetic patients (20 men and 16 women) died. In addition, DNA samples were not available from all original study subjects, and therefore the screening for the 12Glu9 polymorphism of the a 2B AR gene was performed in 126 (58 men and 68 women) non-diabetic subjects and 84 (44 men and 40 women) type 2 diabetic patients.
Clinical and biochemical characteristics
At baseline, the following examinations were done: clinical history (including data on cardiovascular and other diseases, medication, smoking and leisure time physical activity), measurements of anthropometric characteristics and blood pressure, an oral glucose tolerance test and plasma insulin. At the 5 and 10 y examinations, the measurements done at baseline were repeated, and in addition the waist and hip circumferences were measured, as well as plasma C-peptide and glycosylated hemoglobin A 1c (HbA 1c ). The exclusion criteria for the study subjects, as well as the methods for performing the oral glucose tolerance test, and the determinations of glucose, insulin and glycosylated hemoglobin samples have been previously reported.
17,18
Determination of the 12Glu9 polymorphism of the a 2B AR gene DNA samples were prepared from peripheral blood leukocytes by proteinaseK-phenol-chloroform extraction method. For genotyping the three-glutamic acid deletion polymorphism of the a 2B AR gene DNA was amplified with polymerase chain reaction (PCR) with primers (OliGold, Eurogentec, Belgium) forward, 5 0 -AGGGTGTTTGTGGGGCATCTCC3-0 , and reverse, 5 0 -CAAGCTGAGGCCGGAGACACTG-3 0 (product size 112 bp for the long allele, and 103 bp for the short allele). PCR amplification was conducted in a 10 ml volume containing 50 ng genomic DNA, 5 pmol of each primer, 10 mmol=l Tris -HCl (pH 8.8), 50 mmol=l KCl, 1.5 mmol=l MgCl, 0.1% Triton X-100, 0.25 U of DNA polymerase (DynaZyme DNA polymerase, Finnzymes, Finland), and 200 mmol=l dNTP. PCR conditions were denaturation at 94 C for 3 min, followed by 35 cycles of denaturation at 94 C for 30 s, annealing at 69 C for 30 s, and extension at 72 C for 1 min with final extension at 72 C for 4 min. The amplified samples were separated on a 3% agarose gel (NuSieve GTG, FMC Bioproducts, Rockland, ME). The long (Glu 12 ) and short (Glu 9 ) alleles were identified based on their different electrophoretic migration rates.
Statistical analyses
All calculations were performed using the SPSS=WIN program version 8.0 (SPSS Inc., Chicago, IL, USA). Data are presented as mean AE s.d., unless otherwise indicated. Statistical significance of the differences between the groups was evaluated with the w 2 test, ANOVA (followed by post hoc Bonferroni tests), or Student's t-test, when appropriate. Hardy -Weinberg's equilibrium was tested by the w 2 test.
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General linear model (GLM) was used when performing within-group analyses or adjusted analyses with covariates. Plasma insulin levels were analyzed after logarithmic transformation to eliminate skewness and kurtosis, but untransformed units are presented.
Results
The characteristics of the study population at the baseline, 5 and 10 y examinations are presented in Table 1 . Among the non-diabetic subjects, the frequency of the 12Glu9 deletion polymorphism of the a 2B AR gene did not differ significantly from that of the type 2 diabetic patients. genotype, and 20 (24%) had the Glu 9 =Glu 9 genotype. These genotype frequencies were found to be in Hardy -Weinberg equilibrium.
In non-diabetic subjects, the 12Glu9 polymorphism was not cross-sectionally associated with body weight or waistto-hip ratio at the baseline, 5 and 10 y examinations (Table  2) . However, the non-diabetic subjects with the Glu 9 =Glu 9 genotype increased their mean body weight during the first 5 y of the follow-up significantly more than those with the Glu 12 =Glu 9 genotype (changes in weight 70.5 AE 6.4 vs 3.4 AE 4.9%; P ¼ 0.034, for the Glu 12 =Glu 9 and Glu 9 =Glu 9 genotypes, respectively, and P ¼ 0.040 for comparison among all three genotypes, Table 2 and Figure 1 ). When the 5 y change in weight was adjusted for age and sex, however, the difference between genotypes was no longer significant. In a subgroup analysis performed separately in non-diabetic men and women, the 5 y changes in weight did not differ significantly between the genotypes among men (P ¼ 0.533). In non-diabetic women, however, those with the Glu 9 =Glu 9 genotype seemed to gain more weight than those with the other two genotypes, although the differences were not statistically significant (data not shown, P ¼ 0.082 for comparison among all three genotypes). Finally, the trend for the 10 y increment of body weight was statistically significant in the non-diabetic subjects with the Glu 9 =Glu 9 genotype (P ¼ 0.012; Figure 1 ). At the 10 y examination, however, no statistically significant differences in the changes of the mean body weight could be observed among the three 12Glu9 polymorphism groups. Also other variables related to obesity and glucose metabolism were not significantly different among the three genotype groups. At baseline, diabetic subjects with the Glu 9 =Glu 9 genotype had significantly lower fasting plasma glucose levels than those with the Glu 12 =Glu 12 genotype (9.8 AE 3.5 vs 12.8 AE 3.7 mmol=l, respectively; P ¼ 0.019). The mean fasting plasma glucose concentration of the heterozygous diabetic subjects was intermediate between those of the two homozygous groups. However, after the adjustment for age, sex, body weight and antihypertensive drug treatment, the difference in glucose levels between the genotype groups was no longer statistically significant. At the baseline, 5 and 10 y examinations, the 12Glu9 polymorphism of the a 2B AR gene was not associated with body weight or waist-to-hip ratio in diabetic subjects, and also no longitudinal associations between the polymorphism and the changes in the mean body weight could be observed (Table 3) .
Discussion
In the present study, the frequency of the 12Glu9 polymorphism of the a 2B AR gene was similar among non-diabetic subjects and type 2 diabetic patients, and did not differ from that reported in a previous study of Finnish subjects. 16 The novel finding of our study was that non-diabetic subjects with the Glu 9 =Glu 9 genotype gained more weight than did non-diabetic subjects with other genotypes (Glu 12 = Glu 12 or Glu 12 =Glu 9 ) during the 10 y follow-up. In accordance with the study by Heinonen et al 16 we could not find any cross-sectional association between the 12Glu9 polymorphism of the a 2B AR gene and body weight either in non-diabetic or type 2 diabetic subjects. These findings, as well as the similar frequencies of the 12Glu9 polymorphism of the a 2B AR gene reported among both obese and non-obese subjects 16 suggest that this polymorphism is not likely to be a major independent factor affecting obesity in Finnish subjects. However, in the study by Heinonen et al, the Glu 9 =Glu 9 genotype was found to be associated with reduced BMR in obese, non-diabetic Finns. A low basal metabolic rate a 2B -Adrenoceptor polymorphism and body weight K Sivenius et al has been shown to be a risk factor for body weight gain 20 and therefore the results of the present long-term study are in agreement with these earlier findings, since we observed that the Glu 9 =Glu 9 genotype predicted greater increase in body weight among non-diabetic control subjects in 10 y followup.
In addition to possible genetic factors, body weight may be influenced by several other factors, eg diet, physical activity, medication and smoking. In the present study, the use of b-blocking agents and diuretics for the treatment of hypertension, as well as smoking history, daily intake of fat and leisure time physical activity were not significantly genotype and the rest of the non-diabetic subjects (data not shown). Our finding that the association of the 12Glu9 polymorphism with weight gain was observed only in nondiabetic subjects could be due to many confounding factors related to treatment and natural history of type 2 diabetes. Diet therapy and weight loss are the cornerstones of treatment of type 2 diabetic patients. Furthermore, the progressive loss of insulin secretion capacity leads to hyperglycemia and often weight loss among these patients. 18 Also, the impact of the polymorphism on body weight regulation could be different in type 2 diabetic patients and in nondiabetic subjects.
Relatively little is known about the functions of the a 2B -adrenoceptor in humans. In a study that used site-directed mutagenesis and transfected Chinese hamster ovary cells (CHO), mutant receptors with the glutamic acid repeat element either deleted or replaced with an equal number of charge-neutral glutamine recidues were found to be resistant to short-term, agonist-dependent, phosphorylationmediated desensitization. 21 In another study, mice with a disrupted a 2B -adrenoceptor gene failed to show the typical blood pressure increase after i.v. injection of subtype-nonselective a 2 -adrenoceptor agonists, whereas the centrally mediated hypotensive action of these agents was significantly accentuated. 13 Altered regulation of vascular resistance may influence BMR either directly through the redistribution of blood flow or through reflex modulation of autonomic nervous system activity. 16 In conclusion, the 12Glu9 deletion polymorphism of the a 2B AR gene (Glu 9 =Glu 9 genotype) predicted greater increase in body weight among non-diabetic subjects but not in type 2 diabetic patients in 10 y follow-up. The molecular and cellular mechanisms behind the previous and present observations of the 12Glu9 polymorphism in association with BMR and body weight gain remain unclear and should be elucidated in further studies.
